Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth

Molecular Endocrinology

Volumn 26, Issue 12, 2012, Pages 2092-2103

  Chesnokova, Vera ^a   Zonis, Svetlana ^a   Wawrowsky, Kolja ^a   Tani, Yuji ^a   Ben Shlomo, Anat ^a   Ljubimov, Vladimir ^a   Mamelak, Adam ^a   Bannykh, Serguei ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CLUSTERIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FORKHEAD TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SECURIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOXL2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; FEMALE; GENE EXPRESSION; GONADOTROPIN SECRETING CELL; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; TUMOR CELL;

ANIMALS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CLUSTERIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA DAMAGE; DNA-BINDING PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GONADOTROPHS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PITUITARY GLAND; PITUITARY NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RNA ISOFORMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA; MURINAE;

EID: 84870349156     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1158     Document Type: Article

References (71)

1. Melmed S 2011 Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257-266
2. Sanno N, Teramoto A, Osamura RY, Horvath E, Kovacs K, Lloyd RV, Scheithauer BW 2003 Pathology of pituitary tumors. Neurosurg Clin N Am 14:25-39, vi
3. Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J, Meij B, Drouin J 2006 Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 20:2871-2886
4. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST, Low MJ, Holsboer F, Stalla GK, Arzt E 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogen-esis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 100:1034-1039
5. Janovick JA, ConnPM2010 Salt bridge integrates GPCR activation with protein trafficking. Proc Natl Acad Sci USA 107:4454-4458
6. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, Helin K, Croce CM, Fusco A 2006 HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9:459-471
7. Fernandez A, Karavitaki N, Wass JA 2010 Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377-382
8. Melmed S 2003 Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603-1618
9. Kovacs K, Horvath E, Vidal S 2001 Classification of pituitary adenomas. J Neurooncol 54:121-127
10. Asa SL, Ezzat S 2009 The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97-126
11. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young Jr WF, Meyer FB, Kuroki T, Riehle DL, Laws Jr ER 2006 Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341-353, discussion 341-353
12. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S 2008 p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105:17498-17503
13. Chesnokova V, Zonis S, Zhou C, Ben-Shlomo A, Wawrowsky K, Toledano Y, Tong Y, Kovacs K, Scheithauer B, Melmed S 2011 Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One 6:e17924
14. Bettuzzi S, Hiipakka RA, Gilna P, Liao ST 1989 Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J 257:293-296
15. Cheng CY, Chen CL, Feng ZM, Marshall A, Bardin CW 1988 Rat clusterin isolated from primary Sertoli cell-enriched culture medium is sulfated glycoprotein-2 (SGP-2). Biochem Biophys Res Commun 155:398-404
16. de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J 1990 Apolipoprotein J: structure and tissue distribution. Biochemistry 29:5380-5389
17. Wilson MR, Easterbrook-Smith SB 2000 Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25:95-98
18. Kirszbaum L, Bozas SE, Walker ID 1992 SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 297:70-76
19. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR 1999 Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274:6875-6881
20. Jenne DE, Tschopp J 1989 Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 86:7123-7127
21. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ 2004 Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res 64:7412-7419
22. Rizzi F, Caccamo AE, Belloni L, Bettuzzi S 2009 Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol 219:314-323
23. Trougakos IP, Djeu JY, Gonos ES, Boothman DA 2009 Advances and challenges in basic and translational research on clusterin. Cancer Res 69:403-406
24. Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA 2003 Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol Ther 2:372-380
25. Goetz EM, Shankar B, Zou Y, Morales JC, Luo X, Araki S, Bachoo R, Mayo LD, Boothman DA 2011 ATM-dependent IGF-1 induction regulates secretory clusterin expression afterDNAdamage and in genetic instability. Oncogene 30:3745-3754
26. Chen X, Halberg RB, Ehrhardt WM, Torrealba J, Dove WF 2003 Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci USA 100:9530-9535
27. Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M, Thomas-Tikhonenko A 2009 Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. Adv Cancer Res 105:115-132
28. Buttyan R, Olsson CA, Pintar J, Chang C, Bandyk M, Ng PY, Sawczuk IS 1989 Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 9:3473-3481
29. Bettuzzi S, Strocchi P, Marinelli M, Astancolle S, Davalli P, Corti A 1994 Gene relaxation and aging: changes in the abundance of rat ventral prostate SGP-2 (clusterin) and ornithine decarboxylase mRNAs. FEBS Lett 348:255-258
30. Boothman DA, Meyers M, Fukunaga N, Lee SW 1993 Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells. Proc Natl Acad Sci USA 90:7200-7204
31. Miyake H, Nelson C, Rennie PS, Gleave ME 2000 Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60:2547-2554
32. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY 2005 Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7:909-915
33. Rizzi F, Bettuzzi S 2010 The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 17:R1-R17
34. Petropoulou C, Trougakos IP, Kolettas E, Toussaint O, Gonos ES 2001 Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett 509:287-297
35. Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A 2009 Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst 101:663-677
36. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, Ricci S, el-Deiry W, Aronow B, Kaya G, Saurat JH, French LE 2004 Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res 64:3126-3136
37. Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, Corti A 2004 The chemopreventive action of catechins in the TRAMPmouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 25:2217-2224
38. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A, Bettuzzi S 2004 Clusterin (SGP-2, ApoJ) expression is downregulated in low-and high-grade human prostate cancer. Int J Cancer 108:23-30
39. Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A 2009 Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene 28:4344-4352
40. Egashira N, Takekoshi S, Takei M, Teramoto A, Osamura RY 2011 Expression of FOXL2 in human normal pituitaries and pituitary adenomas. Mod Pathol 24:765-773
41. Ellsworth BS, Egashira N, Haller JL, Butts DL, Cocquet J, Clay CM, Osamura RY, Camper SA 2006 FOXL2 in the pituitary: molecular, genetic, and developmental analysis. Mol Endocrinol 20: 2796-2805
42. Pei L, Melmed S 1997 Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11:433-441
43. Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, Wawrowsky K, Melmed S 2005 Early multipotential pituitary focal hyperplasia in the +-subunit of glycoprotein hormone-driven pituitary tumortransforming gene transgenic mice. Mol Endocrinol 19:1383-1391
44. Vlotides G, Eigler T, Melmed S 2007 Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28:165-186
45. Danila DC, Zhang X, Zhou Y, Dickersin GR, Fletcher JA, Hedley-Whyte ET, Selig MK, Johnson SR, Klibanski A 2000 A human pituitary tumor-derived folliculostellate cell line. J Clin Endocrinol Metab 85:1180-1187
46. Alarid ET, Windle JJ, Whyte DB, Mellon PL 1996 Immortalization of pituitary cells at discrete stages of development by directed oncogenesis in transgenic mice. Development 122:3319-3329
47. Cochrane DR, Wang Z, Muramaki M, Gleave ME, Nelson CC 2007 Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem 282:2278-2287
48. Horton P, Park KJ, Obayashi T, Fujita N, Harada H, Adams-Collier CJ, Nakai K 2007 WoLF PSORT: protein localization predictor. Nucleic Acids Res 35:W585-587
49. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S 1999 Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84:761-767
50. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, Mount M, Melmed S 2006 Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147:4781-4791
51. Malik MT, Kakar SS 2006 Regulation of angiogenesis and invasion by human pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer 5:61
52. Shen KC, Heng H, Wang Y, Lu S, Liu G, Deng CX, Brooks SC, Wang YA 2005 ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res 65:8747-8753
53. Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, Celeste A, Manis JP, van Deursen J, Nussenzweig A, Paull TT, Alt FW, Chen J 2006 MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 21:187-200
54. McManus KJ, Hendzel MJ 2005 ATM-dependent DNA damageindependent mitotic phosphorylation of H2AX in normally growing mammalian cells. Mol Biol Cell 16:5013-5025
55. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC 2004 Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 6:168-170
56. Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD, BoothmanDA2005 Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280:14212-14221
57. Klokov D, Leskov K, Araki S, Zou Y, Goetz EM, Luo X, Willson D, Boothman DA 5 Mar 2012 Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGF+1 signaling to confer a pro-survival bystander effect. Oncogene 10.1038/onc.2012.64
58. Klokov D, Criswell T, Leskov KS, Araki S, Mayo L, Boothman DA 2004 IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutat Res 568:97-110
59. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES 2004 Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64:1834-1842
60. Sherr CJ, Roberts JM 1999 CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512
61. Fox PM, Vought VE, Hanazawa M, Lee MH, Maine EM, Schedl T 2011 Cyclin E and CDK-2 regulate proliferative cell fate and cell cycle progression in the C. elegans germline. Development 138: 2223-2234
62. Li J, Antonyak M, Peng X 2012 Indirect immunostaining on mouse embryonic heart for the detection of proliferated cardiomyocyte. Methods Mol Biol 843:139-146
63. Vousden KH, Prives C 2009 Blinded by the light: the growing complexity of p53. Cell 137:413-431
64. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S 2007 Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67: 10564-10572
65. Wang Z, Yu R, Melmed S 2001 Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 15:1870-1879
66. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S 2004 Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Res 64:6174-6182
67. Gartel AL 2007 p21(WAF1/CIP1) may be a tumor suppressor after all. Cancer Biol Ther 6:1171-1172
68. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S 2005 Pituitary hypoplasia in Pttg+/+ mice is protective for Rb+/+ pituitary tumorigenesis. Mol Endocrinol 19:2371-2379
69. Burgering BM, Medema RH 2003 Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/ Akt is off duty. J Leukoc Biol 73:689-701
70. Medema RH, Kops GJ, Bos JL, BurgeringBM2000 AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404:782-787
71. Perreault N, Katz JP, Sackett SD, Kaestner KH 2001 Foxl1 controls the Wnt/+-catenin pathway by modulating the expression of proteoglycans in the gut. J Biol Chem 276:43328-43333